Biblio
Export 2397 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is S [Clear All Filters]
“Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1371-1383, 2022.
, “Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1137-1145, 2022.
, “Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1137-1145, 2022.
, “Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1137-1145, 2022.
, “The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 629-640, 2022.
, “Pelargonidin and Berry Intake Association with Alzheimer's Disease Neuropathology: A Community-Based Study.”, J Alzheimers Dis, vol. 88, no. 2, pp. 653-661, 2022.
, “Perivascular Space Predicts Brain Hypometabolism of Individuals with Underlying Amyloid Pathology.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1329-1337, 2022.
, “Perivascular Space Predicts Brain Hypometabolism of Individuals with Underlying Amyloid Pathology.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1329-1337, 2022.
, “Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1229-1238, 2022.
, “Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1229-1238, 2022.
, “Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1483-1492, 2022.
, “Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1483-1492, 2022.
, “Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 503-518, 2022.
, “Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 503-518, 2022.
, “Progression from Subjective Cognitive Decline to Mild Cognitive Impairment or Dementia: The Role of Baseline Cognitive Performance.”, J Alzheimers Dis, vol. 86, no. 4, pp. 1763-1774, 2022.
, “Race Differences in the Association Between Sleep Medication Use and Risk of Dementia.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1133-1139, 2022.
, “Relationship Between Weight-Change Patterns and Cognitive Function: A Retrospective Study.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1085-1095, 2022.
, “Relationships Between the Deposition of Amyloid-β and Tau Protein and Glymphatic System Activity in Alzheimer's Disease: Diffusion Tensor Image Study.”, J Alzheimers Dis, vol. 90, no. 1, pp. 295-303, 2022.
, “Relationships Between the Deposition of Amyloid-β and Tau Protein and Glymphatic System Activity in Alzheimer's Disease: Diffusion Tensor Image Study.”, J Alzheimers Dis, vol. 90, no. 1, pp. 295-303, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “The Role of Amyloid-β, Tau, and α-Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 89, no. 3, pp. 1039-1049, 2022.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “Salivary Proteomics Reveals Significant Changes in Relation to Alzheimer's Disease and Aging.”, J Alzheimers Dis, vol. 89, no. 2, pp. 605-622, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
,